RIPE-KG · Version 1.1.0 · Resource
ripekg:author/RIPEAUF9FC5FC745E45C59
https://w3id.org/ripe/ripe-kg/author/RIPEAUF9FC5FC745E45C59
| Subject | Predicate | Object |
|---|---|---|
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |
rdf:type |
node1 |
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |
rdf:type |
rdfs:Resource |
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |
rdf:type |
owl:Thing |
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |
rdf:type |
prov:Person |
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |
rdf:type |
foaf:Person |
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |
rdf:type |
ripe:AuthorAuthor |
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |
owl:sameAs |
https://semopenalex.org/author/A5100637658 |
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |
foaf:familyName |
Li |
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |
foaf:givenName |
Huiyuan |
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |
foaf:name |
Huiyuan Li |
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
dcterms:creator |
ripekg:author/RIPEAUF9FC5FC745E45C59Huiyuan Li |